Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri

This article was originally published in The Pink Sheet Daily

Executive Summary

A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.

You may also be interested in...



FDA To Send Draft Ranexa Label Shortly

CV Therapeutics CEO is bullish on clearance in first-line angina.

FDA To Send Draft Ranexa Label Shortly

CV Therapeutics CEO is bullish on clearance in first-line angina.

Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia

Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel